tirzepatide · Eli Lilly
What should I know about Mounjaro?
Mounjaro by Eli Lilly: Type 2 diabetes. Cost, side effects, dosing as labeled, comparisons and the latest news, all sourced.
Start hereMounjaro FAQ: The Questions People Ask GoogleWhat Mounjaro is approved for in 2026, what it costs with and without insurance, why children as young as 10 can now be prescribed it, what the new heart indication does and does not claim, how long a pen survives outside the fridge, and how to check that a box is real.
Medications
Every GLP-1 Drug Ranked by Effectiveness, Using Trial DataA ranking of the GLP-1 and incretin drugs approved in the US, built from published trial results rather than marketing claims — including which comparisons are direct head-to-head trials and which are educated guesses.Every Mounjaro and Zepbound Dose, Pen and VialTirzepatide now comes in four different devices across two brands and six strengths each. This is the complete catalog: what every dose looks like, the NDC numbers, how many doses each device holds, why the multi-dose versions use a different formulation, and how long each one lasts outside the refrigerator.Mounjaro vs Zepbound: What's the Difference?Mounjaro and Zepbound contain exactly the same drug, tirzepatide, made by the same company. What separates them is the FDA-approved use printed on the box, the devices each brand comes in, and the price you actually pay. Here is the full comparison, straight from the two labels.Ozempic vs Mounjaro: How the Two Diabetes Shots CompareOzempic and Mounjaro are both once-weekly injections for type 2 diabetes, but they are different molecules with different dosing ladders, different extra indications and different device options.
Culture
Celebrities on Mounjaro and Zepbound: A Sourced ListA list of public figures who have said, in their own words, that they used tirzepatide - either Mounjaro or Zepbound - with the date, the outlet and what they actually said, plus a clear line between unpaid disclosures and paid brand partnerships.How Many Americans Take Zepbound or Mounjaro: The NumbersNo survey publishes a clean count of US Zepbound or Mounjaro users, so this guide assembles what is actually measured - prescriptions, revenue, market share and poll numbers - and explains what each one does and does not tell you.
Compounded & telehealth
Compounded Tirzepatide: What It Is and Whether It's Legal in 2026Compounded tirzepatide is a pharmacy-mixed version of the active ingredient in Mounjaro and Zepbound. It is not FDA-approved. Since the shortage ended, only narrow patient-specific compounding remains lawful — here's what changed, what's still allowed, and what to ask.How to Spot Fake Mounjaro or ZepboundCounterfeit tirzepatide is sold on social media, through offshore websites and at some med-spas. Here is what a genuine Mounjaro or Zepbound pen looks like, what regulators and Eli Lilly have found inside fakes, and the checks you can run before you inject anything.
Cost & insurance
Does Medicare Cover Zepbound or Mounjaro?Medicare cannot cover a drug used only for weight loss, but there are now three separate doors to tirzepatide: Part D covers Mounjaro for type 2 diabetes, Part D can cover Zepbound for obstructive sleep apnea, and the Medicare GLP-1 Bridge covers the Zepbound KwikPen at $50 a month through 2027. Here is which door you qualify for.How Much Does Mounjaro Cost in 2026?Mounjaro's list price is $1,112.16 for a 28-day supply, but very few people pay it. With commercial insurance that covers it, Lilly's savings card can bring a fill to $25. Paying cash through LillyDirect, Lilly lists it as starting at $499 a month at every dose. Here is the full 2026 price map, including Medicare, Medicaid, TRICARE and why Zepbound costs less for the same molecule.The Cheapest Way to Get Tirzepatide Legally in 2026Seven legal routes to tirzepatide, ranked by what they actually cost in 2026, with the catch attached to each. The cheapest legitimate route for most cash payers is Eli Lilly's own self-pay channel at $299 to $449 a month, and the biggest hidden cost is not the pharmacy you choose but the 45-day refill clock.The Zepbound Savings Card ExplainedThere are three different Lilly offers people call 'the Zepbound coupon,' and they land on $25, $499 or $299 depending on your insurance and which device your prescription names. Here is which one applies to you, the caps that decide whether you actually reach $25, and who is shut out.
Side effects & safety
Does Zepbound Cause Hair Loss? What the Label and the Studies Actually SayHair loss is a listed Zepbound side effect with real numbers behind it. Here is how common it was in the trials, why it affected women far more than men, what the newest population studies found, and why researchers think rapid weight loss is doing most of the work.Mounjaro and Zepbound Lawsuits: What Is Actually Alleged, and Where the Cases StandA plain-English account of the tirzepatide litigation: which injuries are alleged, which courts are handling it, what Eli Lilly argues in its own filings, and what has and has not been decided as of September 2026.Mounjaro Side Effects: What the FDA Label Actually ReportsThe full list of Mounjaro (tirzepatide) side effects from the FDA prescribing information, with trial percentages, the ten warnings, what the four-year SURPASS-CVOT trial found, and how the Mounjaro label differs from Zepbound's.Tirzepatide vs Semaglutide Side Effects: What the Head-to-Head Evidence ShowsA direct comparison of Zepbound and Mounjaro against Wegovy and Ozempic on side effects, using the one randomized head-to-head trial, the best observational study, and the differences written into the two labels.Zepbound and Alcohol: What the Label Says, and Why People Report Drinking LessThere is no alcohol interaction on the Zepbound or Mounjaro label. The real concerns are indirect — dehydration, low blood sugar with insulin, and pancreatitis risk — and separately, a growing body of research finds people on tirzepatide drink less.
Specific groups
GLP-1 Drugs and Men's Health: Testosterone, Sex, Muscle and ResultsMen lose less percentage weight than women on the same dose, their testosterone tends to rise as they lose weight, the erectile function evidence points in two directions at once, and the muscle question is real. Here is what the 2025-2026 research actually found.GLP-1 Drugs for Teens: What Parents Should Know in 2026Two GLP-1 medicines are FDA-approved for adolescents with obesity, one is approved for children as young as 10 with type 2 diabetes, and none are approved under 12 for weight. Here is what the trials found, what the American Academy of Pediatrics guideline says, and what questions are still genuinely open.GLP-1s for Type 1 Diabetes: What the Research Shows in 2026No GLP-1 or dual incretin drug is approved for type 1 diabetes anywhere, and the Wegovy label says use in type 1 diabetes has not been evaluated. But a randomized trial, a Danish national cohort and UK real-world data now exist - and they say something more specific than 'off-label.'Who Should Not Take GLP-1 Drugs, According to the LabelsThe FDA labels for Wegovy, Ozempic, Zepbound and Mounjaro list exactly two absolute contraindications each. Everything else - pancreatitis, gallbladder disease, gastroparesis, pregnancy, surgery, eye disease - sits in warnings, 'not recommended' statements, and gaps where nobody has studied the question at all. Here is the actual list.
Results & daily life
GLP-1 Plateau: Why Weight Loss Stalls and What the Research SaysPlateaus on semaglutide and tirzepatide are expected, measurable and well described in the trial data. Here is how researchers define a plateau, when it typically arrives, why it happens, and what the studies say about what comes next.How Fast Does Zepbound Work? What the Trial Curves ShowA month-by-month look at tirzepatide's weight-loss curve from SURMOUNT-1 and the FDA label — when the dose is reached, when most of the loss happens, when people plateau, and what happens to late responders.
How they work
How Does Mounjaro Work? The Science Behind Tirzepatide, in Plain EnglishMounjaro is tirzepatide, a once-weekly injection for type 2 diabetes that copies two gut hormones instead of one. Here is what it does to insulin, glucagon, your stomach and your appetite, straight from the FDA label and the research behind it.How Long Does Tirzepatide Stay in Your System?Tirzepatide has a half-life of about five days, so after a last dose it takes roughly three and a half to four weeks to clear. Here is what the label says about half-life, steady state, missed doses, washout and what happens when you stop.Semaglutide vs Tirzepatide: How the Two Drugs Actually DifferSemaglutide hits one receptor, tirzepatide hits two - and in the only head-to-head trial, tirzepatide produced more weight loss, though the two molecules differ in more ways than a single number captures.Tirzepatide and Birth Control: What the Label Actually SaysMounjaro and Zepbound are the only once-weekly GLP-1-family drugs whose US labels carry a specific oral contraceptive warning. Here is the exact wording, the study numbers behind it, and how it differs from semaglutide.
FDA & regulation
Is Tirzepatide Still in Shortage? The Full Mounjaro and Zepbound TimelineTirzepatide came off the FDA drug shortage list on October 2, 2024, was put back under review after a lawsuit, and was declared resolved again on December 19, 2024. It has stayed off the list ever since, and courts have upheld that decision twice.The Complete FDA Approval History of Tirzepatide (Mounjaro and Zepbound)Tirzepatide has two US brand names, two application numbers and six separate approved uses. Here is every FDA decision from the May 13, 2022 Mounjaro approval through the August 2026 cardiovascular indication, with the supplement numbers and trial names behind each one.Tirzepatide Approvals Around the World: Mounjaro and Zepbound by CountryTirzepatide is approved in the US, EU, UK, Canada, Japan, China, Australia, India and beyond, but the brand names and the approved uses differ by country. In the UK and EU, Mounjaro is also the weight-loss brand, which trips up a lot of American readers.
Beyond weight loss
Microdosing Zepbound: What's Actually KnownNo randomized trial has ever tested intentional microdosing of tirzepatide. But 2026 brought three things that change the conversation: a US multi-dose pen, a randomized trial of dose reduction, and an FDA proposal to shut down compounded supply.Tirzepatide for PCOS: What the Evidence Actually ShowsTirzepatide is not approved for polycystic ovary syndrome anywhere. One small randomized trial, a large real-world cohort and a newly launched phase 4 trial are the whole evidence base — and they point in a specific, limited direction.What Else Can Tirzepatide Treat? Beyond Weight Loss and DiabetesTirzepatide has exactly four FDA-approved uses in the United States, split across two brand names. Everything else you have read about it — heart failure, fatty liver, PCOS, addiction, dementia — sits somewhere on a long ladder between a strong trial and a hopeful database study.
How-to guides
FAQ
Alternatives
Clinical trials
Semaglutide vs Tirzepatide Head to Head: What SURMOUNT-5 FoundSURMOUNT-5 is the only large randomized trial that pitted tirzepatide directly against semaglutide at obesity doses — here are the numbers, the caveats, and what the trial could not measure.What the Clinical Trials Actually Show About TirzepatideA plain-English tour of the tirzepatide evidence base — the SURPASS diabetes trials, the SURMOUNT obesity trials, the heart and sleep apnea studies, what the numbers were, and where the evidence still runs out.
Stopping & switching
News
The Biggest Eli Lilly GLP-1 Stories of 2026 So FarTirzepatide, the Foundayo pill launch, retatrutide's record weight loss, a heart indication for Mounjaro and a lawsuit between the two biggest names in obesity — everything that has moved Eli Lilly's GLP-1 business from January to mid-September 2026.The Biggest Zepbound and Mounjaro Stories of 2025The twelve developments that reshaped tirzepatide in 2025, from the first Medicare opening and the CVS formulary shock to the head-to-head win over Wegovy, a 170% UK price rise, and Eli Lilly becoming the first trillion-dollar drugmaker.Tirzepatide: A Year-by-Year History of Mounjaro and ZepboundHow one molecule went from an experimental diabetes shot in 2022 to two American brands, four approved uses, the world's best-selling medicine, and the drug every new obesity treatment is measured against.
Companies
Recent Mounjaro news
Full timeline- Culture
r/Zepbound passes 233,000 members, r/Mounjaro passes 204,000
- Safety
Health Canada warns on counterfeit and unauthorized Ozempic and Mounjaro sellers
- Competition
Physicians say Mounjaro's cardiovascular approval matters more than expected
- Research
New analysis finds semaglutide and tirzepatide produce similar weight loss in type 2 diabetes
- Business
Lilly says international incretin growth ran at 136% and flags generic supply constraints in Canada
- FDA & regulation
Lilly moves against imports of counterfeit Mounjaro